Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA

This article was originally published in The Tan Sheet

Executive Summary

Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.

Related Content

FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
CPSC Rx-To-OTC Switch Final Rule Published As Gall Loses Chair Nomination
Antihistamine OTC Switch Petition Slated For NDAC Debate May 11
Emergency Contraceptive Bill Passes Virginia House, Faces Senate Fight
CTFA/SDA Antiseptic Drug "Briefing Document" To Urge Regulatory Flexibility
Oral Contraceptives Have Strong Rx-To-OTC Consumer Support - Survey
Schering Sun Care Sales Growth Helps Maintain Slippery Market Lead
Benadryl vs. Claritin
Patent extensions
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts